Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
CDTX
1326
DELISTED
Cidara Therapeutics
CDTX
| $17.3M | ﹤0.01% |
78,322
-35,057
| -31% | -$5.67M |
2025 Q1
3 quarters
|
|
1327
State Street SPDR S&P Bank ETF
KBE
$1.49B
| $17.3M | ﹤0.01% |
284,992
+110,719
| +64% | +$6.52M |
2014 Q3
45 quarters
|
|
1328
Pool Corp
POOL
$5.87B
| $17.2M | ﹤0.01% |
75,232
+1,700
| +2% | +$442K |
2013 Q2
50 quarters
|
|
1329
Commercial Metals
CMC
$7.03B
| $17.2M | ﹤0.01% |
248,372
-10,637
| -4% | -$666K |
2013 Q2
50 quarters
|
|
1330
PUT
Celsius Holdings
CELH
$6.77B
| $17.2M | ﹤0.01% |
375,000
-150,000
| -29% | -$7.56M |
2025 Q2
2 quarters
|
|
1331
BioMarin Pharmaceuticals
BMRN
$11.1B
| $17.1M | ﹤0.01% |
288,547
-566,041
| -66% | -$30.8M |
2013 Q2
50 quarters
|
|
1332
PUT
Pan American Silver
PAAS
$18.9B
| $17.1M | ﹤0.01% |
+330,000
| New | +$13.8M |
2025 Q4
0 quarters
|
|
1333
Kinetik
KNTK
$4.23B
| $17.1M | ﹤0.01% |
473,980
+158,279
| +50% | +$5.72M |
2022 Q1
15 quarters
|
|
1334
CALL
GameStop
GME
$12.5B
| $17.1M | ﹤0.01% |
850,000
+14,500
| +2% | +$325K |
2024 Q2
6 quarters
|
|
1335
Iridium Communications
IRDM
$5.19B
| $17M | ﹤0.01% |
980,847
+442,985
| +82% | +$7.83M |
2013 Q2
50 quarters
|
|
1336
Generac Holdings
GNRC
$12.8B
| $17M | ﹤0.01% |
124,913
+22,296
| +22% | +$3.6M |
2013 Q2
50 quarters
|
|
1337
Sanmina
SANM
$12.3B
| $17M | ﹤0.01% |
113,473
+34,494
| +44% | +$5.09M |
2013 Q2
50 quarters
|
|
1338
Ares Capital
ARCC
$13.5B
| $17M | ﹤0.01% |
841,558
+140,099
| +20% | +$2.83M |
2016 Q3
37 quarters
|
|
1339
EPAM Systems
EPAM
$5.59B
| $17M | ﹤0.01% |
83,089
-615,524
| -88% | -$110M |
2013 Q2
50 quarters
|
|
1340
HealthEquity
HQY
$7.45B
| $17M | ﹤0.01% |
185,104
-29,187
| -14% | -$2.79M |
2016 Q3
37 quarters
|
|
1341
Avis
CAR
$3.93B
| $16.9M | ﹤0.01% |
131,836
+104,887
| +389% | +$14.6M |
2013 Q2
50 quarters
|
|
1342
Medpace
MEDP
$16.7B
| $16.9M | ﹤0.01% |
30,047
+1,828
| +6% | +$1.04M |
2016 Q3
37 quarters
|
|
1343
Boise Cascade
BCC
$2.62B
| $16.9M | ﹤0.01% |
229,057
-69,140
| -23% | -$5.04M |
2013 Q2
50 quarters
|
|
1344
Owens Corning
OC
$9.36B
| $16.8M | ﹤0.01% |
150,293
-93,175
| -38% | -$10.9M |
2013 Q2
50 quarters
|
|
1345
Vanguard Long-Term Corporate Bond ETF
VCLT
$8.48B
| $16.7M | ﹤0.01% |
220,670
+211,023
| +2,187% | +$16.3M |
2024 Q2
6 quarters
|
|
1346
Western Alliance Bancorporation
WAL
$8.33B
| $16.7M | ﹤0.01% |
199,073
-17,646
| -8% | -$1.43M |
2016 Q1
39 quarters
|
|
1347
PTC Therapeutics
PTCT
$5.3B
| $16.7M | ﹤0.01% |
220,196
-19,453
| -8% | -$1.41M |
2013 Q3
49 quarters
|
|
1348
CALL
Warner Bros
WBD
$77.6B
| $16.7M | ﹤0.01% |
580,000
-745,000
| -56% | -$17.4M |
2025 Q1
3 quarters
|
|
1349
PUT
Enphase Energy
ENPH
$4.42B
| $16.7M | ﹤0.01% |
521,000
-115,000
| -18% | -$3.72M |
2024 Q3
5 quarters
|
|
1350
A.O. Smith
AOS
$7.71B
| $16.6M | ﹤0.01% |
248,323
+10,639
| +4% | +$719K |
2013 Q2
50 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.